系统性硬化症治疗的未来:能否设计更好的试验?
本文讨论系统性硬化症(SSc)治疗试验的现状,指出肺动脉高压和间质性肺病领域已有成功试验,但早期弥漫性皮肤型SSc的多个试验(托珠单抗、阿巴西普、利奥西呱)为阴性结果。作者分析阴性试验的可能原因包括试验设计、疗程不足和检验效能不够,并提出未来试验设计的改进方向。
要点
- SSc相关肺动脉高压联合治疗及间质性肺病新药试验已取得成功。
- 早期弥漫性皮肤型SSc的托珠单抗、阿巴西普、利奥西呱试验未达主要终点。
- 阴性试验不一定代表治疗无效,需考虑设计、疗程和检验效能等因素。
核心结论
- SSc试验阴性结果不一定意味着治疗无效,试验设计、疗程和检验效能等因素可能导致阴性结果。
研究设计与样本
- 本文为系列论文(Series paper),作者讨论SSc治疗试验阴性结果的可能原因及对未来试验设计的启示。
主要发现
- 肺动脉高压联合治疗试验及延缓间质性肺病肺功能下降的新药试验取得成功。
- 早期弥漫性皮肤型SSc的托珠单抗、阿巴西普和利奥西呱试验为阴性,尽管皮肤评分等终点改善接近统计学显著性。
- 马西替坦治疗这些患者数字溃疡的试验结果也令人失望。
临床怎么用
- 解读SSc阴性试验时需综合考虑试验设计、疗程和检验效能,而非直接判定治疗无效。
- 未来SSc试验设计应借鉴阴性试验的教训,优化设计要素。
局限性
- 本文为观点性系列论文,未报告原始研究数据或系统检索方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Strides have been made in the treatment of pulmonary arterial hypertension and interstitial lung disease in patients with systemic sclerosis, with successful trials of combination therapies in pulmonary arterial hypertension and of new drugs that slow the decline of lung function in interstitial lung disease. However, many trials in patients with early diffuse cutaneous systemic sclerosis have been negative, including trials of tocilizumab, abatacept, and riociguat, despite improvements in skin scores and other endpoints that approached statistical significance. Trials of macitentan for digital ulcers in these patients have also been disappointing. Trials that do not meet their primary endpoint do not necessarily signify ineffective therapies, as there are many other possible reasons for negative trial results, including features of trial design, insufficient trial duration, or insufficient power to detect differences between groups. In this Series paper, I discuss some of these reasons and what the research community can learn from negative trials to inform future trial design going forward.
引用
- Pope JE. The future of treatment in systemic sclerosis: can we design better trials? Lancet Rheumatol. 2020. PMID: 38263656. doi:10.1016/S2665-9913(20)30010-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。